Preventive long-term effects of a topical film-forming medical device with ultra-high uv protection filters and dna repair enzyme in xeroderma pigmentosum: A retrospective study of eight cases

Sandra Giustini, Emanuele Miraglia, Enzo Berardesca, Massimo Milani, Stefano Calvieri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Skin cancer is common in xeroderma pigmentosum (XP) due to a DNA repair mechanisms genetic defect. Ultraviolet (UV) exposure is the main cause of increased incidence of actinic keratosis (AK), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) observed in XP subjects. Photoprotection is therefore a mandatory strategy in order to reduce skin damage. A topical DNA repair enzyme has been shown to slow down the development of skin lesions in XP. However, there are no data regarding the effects of photoprotection combined with DNA repair strategies in this clinical setting. A film-forming medical device containing the DNA repair enzyme photolyase and very high-protection UV film lters (Eryfotona AK-NMSC, Ery) is currently available. We report retrospective data regarding the use of Ery in 8 patients (5 women, 3 men) with a diagnosis of XP treated for at least 12 consecutive months, comparing the rate of new skin lesions (AK, BCC and SCC) during active treatment with Ery and during 12 months just before the use of the product. New AK, BCC and SCC mean lesion numbers during the 1-year Ery treatment were 5, 3 and 0, respectively in comparison with 14, 6.8 and 3 lesions, respectively during the 1-year pre-treatment period. Ery use was associated with a 65% reduction in appearance of new AK lesions and with 56 and 100% reductions in the incidence of new BCC and SCC lesions, respectively. These data suggest that topical use of photoprotection and DNA repair enzyme could help lower skin cancer lesions in XP. Control prospective trials are advisable in this clinical setting.

Original languageEnglish
Pages (from-to)222-226
Number of pages5
JournalCase Reports in Dermatology
Volume6
Issue number3
DOIs
Publication statusPublished - May 22 2014

Fingerprint

Actinic Keratosis
Xeroderma Pigmentosum
Basal Cell Carcinoma
DNA Repair Enzymes
Retrospective Studies
Squamous Cell Carcinoma
Equipment and Supplies
Enzymes
Skin Neoplasms
DNA Repair
Skin
Deoxyribodipyrimidine Photo-Lyase
Incidence
Therapeutics

Keywords

  • Non-melanoma skin cancer
  • Photolyase
  • Sunscreen
  • Xeroderma pigmentosum

ASJC Scopus subject areas

  • Dermatology

Cite this

Preventive long-term effects of a topical film-forming medical device with ultra-high uv protection filters and dna repair enzyme in xeroderma pigmentosum : A retrospective study of eight cases. / Giustini, Sandra; Miraglia, Emanuele; Berardesca, Enzo; Milani, Massimo; Calvieri, Stefano.

In: Case Reports in Dermatology, Vol. 6, No. 3, 22.05.2014, p. 222-226.

Research output: Contribution to journalArticle

@article{49608dc4b4ae48b2ad9e82f02bffaff4,
title = "Preventive long-term effects of a topical film-forming medical device with ultra-high uv protection filters and dna repair enzyme in xeroderma pigmentosum: A retrospective study of eight cases",
abstract = "Skin cancer is common in xeroderma pigmentosum (XP) due to a DNA repair mechanisms genetic defect. Ultraviolet (UV) exposure is the main cause of increased incidence of actinic keratosis (AK), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) observed in XP subjects. Photoprotection is therefore a mandatory strategy in order to reduce skin damage. A topical DNA repair enzyme has been shown to slow down the development of skin lesions in XP. However, there are no data regarding the effects of photoprotection combined with DNA repair strategies in this clinical setting. A film-forming medical device containing the DNA repair enzyme photolyase and very high-protection UV film lters (Eryfotona AK-NMSC, Ery) is currently available. We report retrospective data regarding the use of Ery in 8 patients (5 women, 3 men) with a diagnosis of XP treated for at least 12 consecutive months, comparing the rate of new skin lesions (AK, BCC and SCC) during active treatment with Ery and during 12 months just before the use of the product. New AK, BCC and SCC mean lesion numbers during the 1-year Ery treatment were 5, 3 and 0, respectively in comparison with 14, 6.8 and 3 lesions, respectively during the 1-year pre-treatment period. Ery use was associated with a 65{\%} reduction in appearance of new AK lesions and with 56 and 100{\%} reductions in the incidence of new BCC and SCC lesions, respectively. These data suggest that topical use of photoprotection and DNA repair enzyme could help lower skin cancer lesions in XP. Control prospective trials are advisable in this clinical setting.",
keywords = "Non-melanoma skin cancer, Photolyase, Sunscreen, Xeroderma pigmentosum",
author = "Sandra Giustini and Emanuele Miraglia and Enzo Berardesca and Massimo Milani and Stefano Calvieri",
year = "2014",
month = "5",
day = "22",
doi = "10.1159/000368182",
language = "English",
volume = "6",
pages = "222--226",
journal = "Case Reports in Dermatology",
issn = "1662-6567",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Preventive long-term effects of a topical film-forming medical device with ultra-high uv protection filters and dna repair enzyme in xeroderma pigmentosum

T2 - A retrospective study of eight cases

AU - Giustini, Sandra

AU - Miraglia, Emanuele

AU - Berardesca, Enzo

AU - Milani, Massimo

AU - Calvieri, Stefano

PY - 2014/5/22

Y1 - 2014/5/22

N2 - Skin cancer is common in xeroderma pigmentosum (XP) due to a DNA repair mechanisms genetic defect. Ultraviolet (UV) exposure is the main cause of increased incidence of actinic keratosis (AK), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) observed in XP subjects. Photoprotection is therefore a mandatory strategy in order to reduce skin damage. A topical DNA repair enzyme has been shown to slow down the development of skin lesions in XP. However, there are no data regarding the effects of photoprotection combined with DNA repair strategies in this clinical setting. A film-forming medical device containing the DNA repair enzyme photolyase and very high-protection UV film lters (Eryfotona AK-NMSC, Ery) is currently available. We report retrospective data regarding the use of Ery in 8 patients (5 women, 3 men) with a diagnosis of XP treated for at least 12 consecutive months, comparing the rate of new skin lesions (AK, BCC and SCC) during active treatment with Ery and during 12 months just before the use of the product. New AK, BCC and SCC mean lesion numbers during the 1-year Ery treatment were 5, 3 and 0, respectively in comparison with 14, 6.8 and 3 lesions, respectively during the 1-year pre-treatment period. Ery use was associated with a 65% reduction in appearance of new AK lesions and with 56 and 100% reductions in the incidence of new BCC and SCC lesions, respectively. These data suggest that topical use of photoprotection and DNA repair enzyme could help lower skin cancer lesions in XP. Control prospective trials are advisable in this clinical setting.

AB - Skin cancer is common in xeroderma pigmentosum (XP) due to a DNA repair mechanisms genetic defect. Ultraviolet (UV) exposure is the main cause of increased incidence of actinic keratosis (AK), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) observed in XP subjects. Photoprotection is therefore a mandatory strategy in order to reduce skin damage. A topical DNA repair enzyme has been shown to slow down the development of skin lesions in XP. However, there are no data regarding the effects of photoprotection combined with DNA repair strategies in this clinical setting. A film-forming medical device containing the DNA repair enzyme photolyase and very high-protection UV film lters (Eryfotona AK-NMSC, Ery) is currently available. We report retrospective data regarding the use of Ery in 8 patients (5 women, 3 men) with a diagnosis of XP treated for at least 12 consecutive months, comparing the rate of new skin lesions (AK, BCC and SCC) during active treatment with Ery and during 12 months just before the use of the product. New AK, BCC and SCC mean lesion numbers during the 1-year Ery treatment were 5, 3 and 0, respectively in comparison with 14, 6.8 and 3 lesions, respectively during the 1-year pre-treatment period. Ery use was associated with a 65% reduction in appearance of new AK lesions and with 56 and 100% reductions in the incidence of new BCC and SCC lesions, respectively. These data suggest that topical use of photoprotection and DNA repair enzyme could help lower skin cancer lesions in XP. Control prospective trials are advisable in this clinical setting.

KW - Non-melanoma skin cancer

KW - Photolyase

KW - Sunscreen

KW - Xeroderma pigmentosum

UR - http://www.scopus.com/inward/record.url?scp=84929464659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929464659&partnerID=8YFLogxK

U2 - 10.1159/000368182

DO - 10.1159/000368182

M3 - Article

AN - SCOPUS:84929464659

VL - 6

SP - 222

EP - 226

JO - Case Reports in Dermatology

JF - Case Reports in Dermatology

SN - 1662-6567

IS - 3

ER -